Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

BACKGROUND: In the AVAGAST study, fluoropyrimidine and cisplatin plus bevacizumab did not significantly improve overall survival (OS) versus fluoropyrimidine and cisplatin plus placebo in patients with advanced gastric cancer. Geographic differences in efficacy were observed in AVAGAST, but the stud...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Gastric Cancer
Главные авторы: Shen, Lin, Li, Jin, Xu, Jianming, Pan, Hongming, Dai, Guanghai, Qin, Shukui, Wang, Liwei, Wang, Jinwan, Yang, Zhenzhou, Shu, Yongqian, Xu, Ruihua, Chen, Lei, Liu, Yunpeng, Yu, Shiying, Bu, Lilian, Piao, Yongzhe
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Japan 2014
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4544634/
https://ncbi.nlm.nih.gov/pubmed/24557418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-014-0351-5
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы